TrialInternational journal of colorectal disease2008

Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.

Paul Rutgeerts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.